GWM
AVEO

Geneos Wealth Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Geneos Wealth Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-800
Closed -$4K – 3060
2020
Q3 		$4K Buy
+800
New +$3.96K ﹤0.01% 2293

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geneos Wealth Management's AVEO Position: Q4 2020 in Review

Geneos Wealth Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2020, closing a stake of 800 shares — an estimated $4K sold.

Geneos Wealth Management first reported a position in AVEO in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 65 funds tracked by Wall St. Rank hold AVEO as of Q4 2020.

  • Geneos Wealth Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 800 AVEO Pharmaceuticals, Inc. shares in Q4 2020, an estimated $4K.
  • Geneos Wealth Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • Geneos Wealth Management's AVEO Pharmaceuticals, Inc. position peaked at $4K in Q3 2020.
  • 65 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.